English
Back
Download
Log in to access Online Inquiry
Back to the Top

Positive oncology research analysis

The Phase 2a trial data for IMM-1-104 represents a significant breakthrough in pancreatic cancer treatment. The 43% overall response rate (ORR) and 86% disease control rate (DCR) in combination with modified gemcitabine/nab-paclitaxel substantially outperform historical benchmarks of 23% ORR and 48% DCR. The 100% tumor reduction in the FOLFIRINOX combination arm and 67% reduction in monotherapy demonstrate remarkable efficacy across multiple treatment settings.

The tolerability profile is particularly noteworthy - the absence of Grade 3/4 adverse events in the monotherapy arm suggests a potential paradigm shift in MEK inhibition. This could enable broader combination strategies and longer treatment durations, critical factors in improving patient outcomes.
Immuneering's Cancer Drug Shows Stunning 43% Response Rate in Pancreatic Cancer Trial
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
2
+0
Translate
Report
3714 Views
Comment
Sign in to post a comment
    Just exploring the app to grow my money. Don't scold me if I'm copying u k 😂
    175
    Followers
    39
    Following
    762
    Visitors
    Follow
    Discussing
    Trump 2.0 Era: What's the next opportunity in the markets?
    ▪️Could Trump's crypto policies potentially benefit the crypto market? ▪️Might his tariff policies have a positive effect on Chinese stocks Show More